高血压病、脑卒中患者血浆GMP-140及vWF的临床研究  

A clinical study on plasma GMP-140 and vWF levels in patients with essential hypertension and cerebral apoplexy

作　　者：卢岑[1] 王小朝[1] 汤立军 

机构地区：[1]广东江门市人民医院,529000

出　　处：《新医学》2000年第2期82-83,共2页Journal of New Medicine

摘　　要：目的：探讨血浆中血小板α颗粒膜蛋白－１４０（ＧＭＰ－１４０）及血管性假血友病因子（ｖＷＦ）在高血压病和有高血压病史的脑卒中的发病过程的作用及临床意义。方法：采用酶联免疫吸附法分别测定高血压病、脑梗死、脑出血患者和正常对照组血浆中ＧＭＰ－１４０及ｖＷＦ的含量，并进行分析。结果：脑梗死、脑出血患者，高血压病患者的血浆ＧＭＰ－１４０及ｖＷＦ的含量均分别高于正常对照组，脑出血患者的血浆ＧＭＰ－１４０的含量高于高血压病组（Ｐ＜０．０５），其余各组之间比较均无显著性差异（Ｐ＞０．０５）。结论：高血压病、脑卒中患者存在血小板高度活化状态和血管内皮细胞受损，这些改变可能参与了这两类疾病的发病过程。对这些患者应针对以上改变采取相应的治疗措施。Objective: Tp study the effects and clinical significance of plasmal platelet alpha granule membrane protein-140 (GMP-140) and von willebrand factor (vWF) levels in patients with essential hypertension (EH) and hypertensive cerebral apoplexy. Methods: Plasma GMP-140 and vWF levels were determined by enzyme-linked immunosorbent assay in controls and in patients with EH, cerebral infarction and cerebral hemorrhage. Results: The levels of plasma GMP-140 and vWF in patients with EH, cerebral infarction, cerebral hemorrhage were significantly higher than in the control group. Patients with cerebral hemorrhage had higher plasma GMP-140 levels than those with EH (p<0.05),but no differences in plasma GMP-140 level were found among other groups (P>0.05). Conclusion: Enchanced activation of platelets and injury of vascular endothelium in patients with EH and cerebral apoplexy may be involved in the development of hypertension and cerebral apoplexy. Appropriate treatment should be adopted targeted on the above abnormality.

关 键 词：高血压 脑卒中 酶联免疫吸附测定 血小板Α颗粒膜蛋白-140 血管性假血友病因子 

分 类 号：R544.1[医药卫生—心血管疾病] R743.3[医药卫生—内科学]